Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009204 · ClinicalTrials.gov registry record · Phase 3
Serotonergic Pharmacotherapy for Agitation of Dementia
A Phase 3 study of Alzheimer Disease and Dementia, sponsored by Bruce Pollock.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00009204: Completed Phase 3 study of Alzheimer Disease and Dementia, sponsored by Bruce Pollock.
NCT00009204 is a Phase 3 study of Alzheimer Disease and Dementia that has completed, run by Bruce Pollock. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009204, a Phase 3 study of Alzheimer Disease and Dementia, has completed, sponsored by Bruce Pollock.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
Conditions Studied
Interventions
- DRUG Citalopram [Celexa]
- DRUG Perphenazine [Trilafon]
Study Locations (1)
Pennsylvania
- University of Pittsburgh Western Psychiatric Institute and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-09 |
| Est. Completion | 2002-04 |
| Phase | Phase 3 |
What the finished NCT00009204 record still lists
NCT00009204 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Citalopram [Celexa] is the first listed.
NCT00009204 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00009204 about?
NCT00009204 is a clinical study titled "Serotonergic Pharmacotherapy for Agitation of Dementia". This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients s...
What is the current status of trial NCT00009204?
This trial is currently completed. It is a Phase 3 study. The study started on 1995-09. Estimated completion is 2002-04.
What conditions does trial NCT00009204 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Dementia, Vascular.
What interventions are being tested in trial NCT00009204?
The interventions under investigation include: Citalopram [Celexa] (DRUG), Perphenazine [Trilafon] (DRUG).
Who is sponsoring clinical trial NCT00009204?
This trial is sponsored by Bruce Pollock, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00009204 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia